Pharmacy Consulting

Pharmacy Healthcare Solutions LLC (PHSL) consults with pharmaceutical manufacturers, PBMs, pharmacies (retail, specialty, mail service, LTC, and hospital outpatient), and technology companies on strategic business and marketing issues. Consulting projects across these market segments provide PHSL with the latest information on emerging trends as well as new products and services. Our consultants have extensive retail, mail service and managed care experience to create actionable recommendations for our clients’ challenging business issues.

Learn More About PHSL Services

News & Events

PHSL to Attend 2024 NACDS Total Store Expo

PHSL President Ann Johnson, Vice President Melissa Krause, Co-Founder Tim Kosty, Senior Consultant Patty Milazzo, and Director of Business Development Karlo Zovko will be attending the 2024 NACDS Total Store Expo on August 17th – 19th in Boston, MA. PHSL will have an exhibit set up at booth #2006. If you would like to schedule a Read More →

Pharmacy Technology & Management Review May/June 2024

PHSL Senior Consultant Patricia Milazzo contributed to the May/June 2024 edition of Pharmacy Technology & Management Review (PTMR). In her Viewpoints article, Patricia discusses pharmacy revenue opportunities through a variety of travel health services as international travel is expected to increase in 2024. Click here to read the article “International Travel — Pharmacy Opportunities.”

Federal Trade Commission Eyeing Drug Patents in Orange Book

The Federal Trade Commission (FTC) has taken the position that certain drug-device patents are not legitimate.  Asthma and COPD inhalers, obesity and type-2 diabetes injectables, glucagon nasal spray, epinephrine autoinjectors, and other drug-device combinations have recently been in the crosshairs of the FTC.   This has created controversy regarding hundreds of patent listings within the Food Read More →

Latest from the Blog

DSCSA Delay and Exemptions

The Drug Supply Chain Security Act (DSCSA), signed in 2013 by President Obama, was set to take effect November 27, 2023. The main purposes of the Act are to give guidance on identifying illegitimate and suspicious products, make recalls more efficient, implement electronic track and trace systems, and define federal licensing standards. The DSCSA affects Read More →

New Indications for Weight Loss Drugs – Positive Implication for Trend?

Hope seems to have emerged in America’s battle of the bulge with the FDA’s 2017 approval of Novo Nordisk’s once weekly injection Ozempic, which quickly became known for its off-label success as a weight-loss drug, despite its indication for type 2 diabetes. The ensuing years brought Wegovy, with its weight loss indication.  These products were Read More →

Manufacturers to Voluntarily Cap Prices on Numerous Inhalers

Three of the four major inhaler manufacturers in the United States have announced the implementation of an inhaler price cap, which is set to take effect this year. Many inhalers have high costs, with uninsured or high-deductible health plan (HDHP) patients often paying $200 to $600 for a one-month supply. However, the price of inhalers Read More →